Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic expertise in action: molecular tumour boards and decision‐making in precision oncology

13 Jun 2019

Abstract excerpt

The recent development of cancer precision medicine is associated with the emergence of 'molecular tumour boards' (MTBs). Attended by a heterogenous set of practitioners, MTBs link genomic platforms to clinical practices by establishing 'actionable' connections between drugs and molecular alterations. Their activities rely on a number of evidential resources - for example databases, clinical trial results, basic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Genetic factors in colorectal cancer
Share to Genomics and Rare Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31197873
DOI: 10.1111/1467-9566.12970

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic expertise in action: molecular tumour boards and decision‐making in precision oncologyPMID 31197873Read ↗

Implementation of a Clinical Decision Support System for Precision Oncology across an Academic NetworkSemantic proximity Read ↗

What Do German Molecular Tumor Boards Recommend in Patients with PIK3CA-Mutated Tumors? Launch and First Results from the German Transsectoral Molecular Tumor Board Exchange Platform Deutschland.Semantic proximity Read ↗

BRCA patients and clinical collectives: new configurations of action in cancer genetics practices.Semantic proximity Read ↗

Cancer clinical trials in the era of genomic signatures: Biomedical innovation, clinical utility, and regulatory-scientific hybridsSemantic proximity Read ↗

Advancing molecular tumour boards: highly needed to maximise the impact of precision medicineSemantic proximity Read ↗

Knowledge Connector: Decision support system for multiomics-based precision oncologySemantic proximity Read ↗

Patient attrition in Molecular Tumour Boards: A ReviewSemantic proximity Read ↗

The WERA Cancer Center Matrix: Strategic Management of Patient Access to Precision Oncology in a Large and Mostly Rural Area of GermanySemantic proximity Read ↗

[The tools for the governance of mutational oncology and agnostic drugs: from place in therapy to place in pathway.]Semantic proximity Read ↗

The Role of Decision Impact Studies in Genomic Medicine in Cancer Care: A Scoping Review and Bibliometric Analysis ProtocolSemantic proximity Read ↗

Validating what counts as knowledge: The algorithmic gaze and nested multifocality in the biosciencesSemantic proximity Read ↗

Mapping the Regional Distribution of Molecular Tumor Board Patients and Identifying White Spots in our Catchment Area – a Joint Approach of the CCC WERA AllianceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.